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Abstract
Background—Cancer is increasingly common among HIV patients given improved survival.
Objective—To examine calendar trends in cumulative cancer incidence and hazard rate by HIV 
status.
Design—Cohort study
Setting—North American AIDS Cohort Collaboration on Research and Design during 1996–
2009
Patients—86,620 HIV-infected and 196,987 uninfected adults
Measurements—We estimated cancer-type-specific cumulative incidence by age 75 years by 
HIV status and calendar era, and examined calendar trends in cumulative incidence and hazard 
rates.
Results—Cumulative incidences (%) of cancer by age 75 (HIV+/HIV−) were: Kaposi sarcoma 
(KS), 4.4/0.01; non-Hodgkin’s lymphoma (NHL), 4.5/0.7; lung, 3.4/2.8; anal, 1.5/0.1; colorectal, 
1.0/1.5; liver, 1.1/0.4; Hodgkin lymphoma (HL), 0.9/0.1; melanoma, 0.5/0.6; and oral cavity/
pharyngeal, 0.8/0.8. Among HIV-infected subjects, we observed decreasing calendar trends in 
cumulative incidence and hazard rate for KS and NHL. For anal, colorectal and liver cancers, 
increasing cumulative incidence, but not hazard rate trends, were due to the decreasing mortality 
rate trend (−9% per year), allowing greater opportunity to be diagnosed with these cancer types. 
Despite decreasing hazard rate trends for lung, HL, and melanoma, we did not observe cumulative 
incidence trends due to the compensating effect of the declining mortality rate on cumulative 
incidence.
Limitations—Secular trends in screening, smoking, and viral co-infections were not evaluated.
Conclusions—Our analytic approach helped disentangle the effects of improved survival and 
changing cancer-specific hazard rates on cumulative incidence trends among HIV patients. 
Cumulative cancer incidence by age 75, approximating lifetime risk in HIV patients, may have 
clinical utility in this population. The high cumulative incidences by age 75 for KS, NHL, and 
lung cancer supports early and sustained ART and smoking cessation.
Primary Funding Source—National Institutes of Health
INTRODUCTION
Antiretroviral therapy (ART) has prolonged the lifespan of HIV-infected patients (1, 2), 
resulting in an increasing number of individuals aging with HIV infection (3). Cancer (4) is 
increasingly common in this population, with a higher burden compared with the general 
population due to both impaired immune function including chronic inflammation (4–12) 
and a higher prevalence of risk factors including smoking (13–16) and viral co-infections 
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(17–19). Among HIV-infected persons, the incidence of AIDS-defining cancers (ADC), 
primarily Kaposi sarcoma (KS) and non-Hodgkin’s lymphoma (NHL), has declined 
substantially in the ART era, but remains elevated compared with uninfected persons (20, 
21). Furthermore, several non-AIDS-defining cancers (NADC), including Hodgkin 
lymphoma (HL) and lung, anal, and oral cavity/pharyngeal (OP) cancers, have also 
exhibited elevated incidence in HIV-infected persons (10, 22–26).
Calendar-era trends in cancer incidence among HIV-infected persons have been evaluated 
using several metrics, including numbers of cases (4), incidence rates (4, 27, 28), and 
cumulative incidence (20). While the number of cases of virtually all NADC types has 
increased due to the growth and aging of the HIV-infected population (4), there have been 
inconsistent cancer-type-specific incidence rate trends (Appendix Table 1). One reason for 
the inconsistent results may be that only one prior study (20) has explicitly accounted for the 
competing risk of death, which is germane given both the higher mortality risk for HIV 
patients compared with the general population, and the dramatic improvements in survival 
over time for HIV patients on ART.
Here, our primary objective was to compare time trends in cumulative cancer incidence in 
HIV-infected and uninfected persons. We used competing risk methods to evaluate trends in 
both cumulative incidence (29) and cancer-specific hazard rates (30) to provide a more 
complete understanding of the reasons for observed changes in cancer risk over time, which 
could be influenced by both the incidence rate of the cancer of interest and the all-cause 
mortality rate (31, 32). In addition, we report cumulative cancer incidence (i.e., cancer risk) 
by age 75 years, a measure that may have clinical and public health utility in this population 
since 75 years approximates the current lifespan for effectively treated HIV-infected adults 
(1). This metric may be a more intuitive measure of cancer burden than the incidence rate, 
and thus may have greater clinical utility.
METHODS
Study design, setting and subjects
Our objective was to estimate the cumulative incidence of nine common cancers by HIV 
status and calendar period. The study population consisted of adults (≥ 18 years) followed 
between 1996 and 2009 in 16 cohorts from the U.S. and Canada participating in the North 
American Cohort Collaboration on Research and Design (NA-ACCORD; Appendix Table 
2) (33). All contributing cohorts submitted comprehensive clinical data on HIV-infected 
subjects using standardized data collection methods. In addition, five cohorts contributed 
data on uninfected subjects (Appendix Table 2) selected to be demographically similar to the 
HIV-infected subjects in the respective cohorts. Institutional Review Board approval was 
obtained for each participating cohort.
Cancer diagnosis validation
The endpoints were nine common incident cancer types: KS, NHL, lung, anal, colorectal, 
liver, and OP cancers, HL, and melanoma. Subjects were evaluated for the first occurrence 
of a specific cancer type, but could contribute follow-up and events for each cancer type. 
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Diagnoses were collected using a web-based standardized abstraction protocol that included 
collection of cancer site and histopathology by manually reviewing medical records and 
pathology reports or by cancer registry linkage (Appendix 2).
Statistical methods
For each subject, observation time began three months after the latest of January 1, 1996, 
NA-ACCORD entry date, or cohort-specific start date for reporting validated cancer 
diagnoses (Appendix Table 2). The three-month window allowed for exclusion of prevalent 
cancers. Each subject was followed until the earliest of December 31, 2009, cancer 
diagnosis date, death date, date lost to follow-up, or cohort-specific end date for reporting 
validated cancer diagnoses (Appendix Table 2).
In all analyses, we used age as the time scale, which accounted for the potentially strong 
confounding effect of age on time trends (34). We focused on cumulative cancer incidence 
by age 75 years as our main measure since this age approximates both the current lifespan 
for effectively treated HIV-infected adults and the upper age limit of our follow-up, with 2% 
and 3% of person-time after age 70 for HIV-infected and uninfected subjects respectively. 
Given the limited follow-up in older ages, we also present cancer risk by age 65. Since we 
did not actually follow individuals from age 18 to 75 years, but at most followed a given 
subject for 14 years, the cumulative incidence metric relied on the assumption that the age-
specific risk of cancer remained constant across birth cohorts, similar to assumptions made 
for life expectancy calculations (35).
We used a competing risk approach with non-parametric estimators for the competing risk 
of death (30, 36, 37) to estimate cumulative cancer incidence by HIV status and calendar 
era, categorized as 1996–1999 (reference), 2000–2004, and 2005–2009. We estimated 
confidence intervals for cumulative incidence by bootstrap methods (38). Next, we 
computed the subdistribution hazard ratio (sdHR) (29) to estimate secular changes in 
cumulative cancer incidence, and the cause-specific hazard ratio (csHR) (30) to estimate 
secular changes in the cancer-specific hazard rate, both adjusted for sex, race (White, Black, 
other including Hispanic, unknown), and study cohort. We assessed linear annual trends by 
assignment of a score corresponding with each calendar era midpoint. Proportionality of 
hazards assumption was assessed by interaction terms between calendar era and age for 
sdHRs and Schoenfeld residuals (39) for csHRs. Evaluating cumulative incidence using a 
competing risk approach, along with sdHRs and csHRs, can provide valuable insights into 
the reasons for changes in cancer risk over time, which may be due to both shifting cancer 
etiology and improvements in overall survival (40). Specifically, in the HIV setting with 
improved survival due to more effective ART, more individuals remain alive to potentially 
experience cancer. Thus, even if the hazard rate (csHR) for a cancer type did not change 
over time, the cumulative incidence (sdHR) would be expected to increase due to the 
declining death rate.
SAS, version 9.3 (SAS Institute, Inc., Cary, North Carolina) was used to calculate the non-
parametric cumulative incidence functions using an in-house programmed macro based 
upon the PROC PHREG procedure in SAS (available from authors upon request). STATA 
13 (StataCorp LP, College Station, Texas) was used to estimate both the subdistribution and 
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cause-specific proportional hazards models using the stcrreg and stcox command, 
respectively. Figures were created in R version 3.1.0 (R Core Team, Vienna, Austria).
The funding sources had no role in the design, conduct, and analysis of the study, or with the 
decision to submit the manuscript for publication.
RESULTS
This investigation included 86,620 HIV-infected (475,660 person-years) and 196,987 
uninfected subjects (1,847,932 person-years) (Appendix Table 2). Most subjects were men 
and fewer than half were known to be white (Table 1). The median age at entry into the 
1996–1999 and 2005–2009 calendar eras increased from 42 to 47 years for HIV-infected 
subjects and from 42 to 48 years for uninfected subjects, and the median birth year at 
calendar era entry increased from 1955 to 1959 for HIV-infected subjects and from 1955 to 
1957 in uninfected subjects, with substantial birth cohort overlap across calendar eras. 
Among HIV-infected subjects, the median CD4 count increased from 309 to 382 cells/ul, 
and despite increasing age, the crude mortality rate decreased from 5,140 to 2,844 deaths per 
100,000 person-years, but even in 2005–2009 was over three-fold higher than in uninfected 
subjects. During 1996–2009, each cancer-type-specific incidence rate was higher among 
HIV-infected compared with uninfected subjects (Table 2), most notably for KS, NHL, anal 
cancer, and HL.
Cumulative cancer incidence
Cumulative cancer incidence by age 65 and 75 years during 1996–2009 was higher among 
HIV-infected compared with uninfected subjects for all cancer types except colorectal, 
melanoma, and OP (Table 3). Among HIV-infected subjects during 1996–2009, cumulative 
incidence by age 75 was highest for KS (4.4%), NHL (4.5%), and lung cancer (3.4%), and 
was 4.1% for KS, 4.0% for NHL, and 3.7% for lung cancer in the most recent calendar era 
(2005–2009) (Figure 1). Among uninfected subjects during 1996–2009, cumulative 
incidence by age 75 was greater than 2% only for lung cancer (2.8%) and was highest for 
lung (2.3%) and colorectal (1.3%) cancers in 2005–2009 (Figure 2).
Calendar trends in cumulative incidence
Among HIV-infected subjects, we observed significant declining annual trends in 
cumulative incidence, as measured by the sdHR (Table 4), for KS (−4% per year), NHL 
(−5% per year), and death (−9% per year) and significant increasing trends for anal (6% per 
year), colorectal (5% per year) and liver (6% per year) cancers. We observed no evidence 
for cumulative incidence trends for lung cancer, HL, melanoma, or OP cancer, although 
given the wide 95% CIs for HL, melanoma, and OP cancer, the absence of trends cannot be 
confirmed. Among uninfected subjects, we observed significant declining trends in 
cumulative incidence for lung (−5% per year), colorectal (−6% per year), melanoma (−7% 
per year), OP (−6% per year), and death (−3% per year), but no significant increasing trends. 
Cumulative incidence trends significantly differed by HIV status for NHL, which decreased 
only in HIV-infected subjects; colorectal, which increased in HIV-infected but decreased in 
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uninfected subjects; lung and OP, both of which decreased only in uninfected subjects; and 
death, for which there was a greater decline in HIV-infected subjects.
Calendar trends in hazard rates
Among HIV-infected subjects, we observed significant declining annual trends in hazard 
rate, as measured by the csHR (Table 4), for KS (−6% per year), NHL (−8% per year), lung 
cancer (−4% per year), HL (−5% per year), melanoma (−6% per year), and death (−9% per 
year). For anal cancer, although the annual calendar trend was not significant, there was 
evidence of a non-linear trend, with similarly increased hazard rates in the 2000–2004 and 
2005–2009 calendar eras compared with 1996–1999 (Appendix Table 3). We observed no 
evidence for hazard rate trends for colorectal, liver, or OP cancer, although the absence of 
trends cannot be confirmed given the wide 95% CIs. Among uninfected subjects, we 
observed significant declining trends in the hazard rate for lung (−6% per year), colorectal 
(−7% per year), melanoma (−8% per year), OP (−7% per year), and death (−3% per year). 
Cancer-specific hazard rate trends significantly differed by HIV status for NHL, which 
declined only in HIV-infected subjects; colorectal and OP, which declined only in 
uninfected subjects; and death, which declined more in HIV-infected than uninfected 
subjects. Furthermore, HIV-infected and uninfected subjects exhibited similar declining 
trends for lung cancer and melanoma.
DISCUSSION
In this investigation, we reported cumulative cancer incidence by age 75 years, a novel use 
of this measure in the HIV-infected population that provides easily interpretable information 
for HIV patients about their long-term cancer risk. Our results indicated that KS, NHL, and 
lung cancer remain of great concern, each with lifetime risks of about 1 in 25 in 2005–2009. 
In addition, the competing risk approach helped disentangle the effects of improved survival 
and changing cancer-specific hazard rates on cumulative incidence trends.
Of seven NADC examined here, we observed increasing cumulative incidence over time for 
anal, colorectal and liver cancers among HIV-infected subjects. It appears that two factors 
contributed to this trend for anal cancer: 1) the declining death rate, which presumably 
allowed more individuals to survive long enough to experience long-term exposure to 
human papillomavirus (HPV) infection (41); and 2) the elevated anal cancer hazard rate 
after 1996–1999. The observed stabilization of the hazard rate at an elevated level after 
1999, consistent with our previous more detailed investigation of anal cancer in NA-
ACCORD (42), might be due to improved immune function associated with more recently-
available ART compared with the early ART era (i.e., 1996–1999), since prior studies have 
suggested an inverse relationship between CD4 count and anal cancer incidence rates (10). 
However, calendar trends in incidence rates (comparable to trends in hazard rates here) 
reported by others for anal cancer have not been consistent (Appendix Table 1) (27, 43–46).
The increasing cumulative incidence trends for liver and colorectal cancers among HIV-
infected subjects appeared to be due primarily to the declining death rate, as an increasing 
trend was not observed in the csHRs for these two cancer types. For liver cancer, the 
increasing trend for HIV-infected subjects was similar in magnitude, and not statistically 
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different from, the trend for liver cancer among uninfected subjects. This similarity may 
reflect the identical nonsignificant increasing hazard rate trends between HIV-infected and 
uninfected subjects, consistent with a general increase in liver cancer risk for ‘baby 
boomers’ (i.e., birth years 1945–1965), who have a higher prevalence of HCV and HBV 
infection than other birth cohorts (47). For colorectal cancer, the increasing cumulative 
incidence trend among HIV-infected subjects was in the opposite direction of the significant 
decreasing cumulative incidence and hazard rate trends among our uninfected subjects, also 
observed in the general population (48). We hypothesize that this disparity in colorectal 
cancer trends may be due to HIV-infected subjects lagging behind the trend of increased 
colorectal cancer screening in the general population (49).
Among HIV-infected subjects, we found no evidence for calendar trends in cumulative 
incidence for four other NADC – lung cancer, HL, melanoma, or OP cancer. For lung 
cancer, HL and melanoma, we did not observe cumulative incidence trends despite 
decreasing hazard rate trends, implying the declining mortality rate counterbalanced the 
declining cancer-specific hazard rates. Notably, for lung cancer, we observed similar 
declining hazard rate trends for HIV-infected and uninfected subjects, consistent with 
general population trends (48) due to a long-term decline in smoking prevalence (50). This 
finding is consistent with similarly declining smoking prevalence by HIV status, suggesting 
that the disparity in cumulative incidence trends – steady in HIV-infected subjects and 
declining in uninfected subjects – was due to the much greater decreasing mortality rate 
trend in HIV-infected subjects.
For melanoma, the significant declining hazard rate trends among both HIV-infected and 
uninfected subjects were the opposite of that observed in the general population although 
only among those of white race (48), whereas less than half of our sample was known to be 
white. We can speculate, but cannot confirm, whether there was more skin cancer screening 
or reduced sun exposure over time among our study subjects compared with the general 
population.
For OP cancer, both the cumulative incidence and hazard rate trends significantly declined 
among uninfected subjects, with no observed trends among HIV-infected subjects. In the 
general population, OP cancer incidence rates declined during 1992–2010, except during 
2003–2010 in males (48). In general, overall OP incidence trends are determined by trends 
in HPV-related OP cancer, which has been increasing in the general population, and in 
HPV-unrelated OP cancer, which is strongly associated with smoking and alcohol 
consumption and has been decreasing in the general population (51–53).
As expected, the cumulative incidences for KS and NHL declined significantly for HIV-
infected subjects, with even stronger hazard rate declines, consistent with prior studies (4, 
22, 23, 28, 54, 55) and resulting from viral suppression and consequent improved immune 
function afforded by ART. In contrast, the cumulative incidence and hazard rate trends for 
NHL did not change over calendar time among uninfected subjects, confirming that 
successful ART has reduced the gap in NHL risk by HIV status (23, 27, 56). We were 
unable to compare trends similarly for KS by HIV status since only three KS cases were 
observed among uninfected subjects.
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The only other studies to use competing risk methods to estimate cumulative cancer 
incidence in immunosuppressed populations were among AIDS patients (20) and organ 
transplant recipients (57), so are not directly comparable to our study. Few recent studies 
have evaluated trends in incidence rates for specific NADC cancer types among HIV-
infected persons exclusively in the ART era, comparable to our evaluation here of calendar 
era csHR trends (27, 42–46). Across studies, trends for incidence rates, analogous to trends 
in hazard rates, have been indeterminate (i.e., not statistically significant) or decreasing for 
lung cancer, HL, and melanoma, indeterminate or increasing for anal (except for one study 
with a decreasing trend) and liver cancer, and indeterminate for colorectal cancer and OP 
cancer (summary provided in Appendix Table 1). Differences across studies may be due to 
differences in statistical power, time periods analyzed, or prevalence of risk factors or cancer 
screening.
Our results have clinical implications regarding cancer screening in HIV patients. Annual 
lung cancer screening with low-dose computed tomography is recommended for heavy 
smokers in the general population aged 55–80 years (58). The high smoking prevalence in 
HIV patients, along with lung cancer incidence comparable to that of ADC, suggest that 
HIV-infected smokers should be compelling candidates for screening. In fact, however, 
research is urgently needed to inform lung cancer screening policy for HIV patients by 
clarifying the benefits versus harms of screening, as there is potential for harms resulting 
from a high false positive rate due to elevated incidence of lung infections and other 
pulmonary diseases (59). The rise in colorectal cancer risk among HIV patients, despite a 
decline in the general population, indicated the need for increased screening among HIV 
patients aged 50–75 years, as recommended for the general population (60). Furthermore, 
the rise in anal cancer risk highlights the need for further evidence regarding the harms and 
benefits of anal dysplasia screening (61). Finally, although there are no formal guidelines, it 
would be prudent for physicians to be alert for early signs and symptoms of KS and NHL.
There are also clinical implications for primary prevention. Development of targeted 
smoking cessation interventions for HIV patients is an obvious priority. The highly effective 
HPV vaccine was licensed in 2011 for the prevention of anal cancer (62). Although there is 
concern that high prevalence of HPV infection among HIV patients might render 
vaccination ineffective, the vaccine has, in fact, been found to be immunogenic in HIV 
patients (63–65), suggesting that vaccination has the potential to substantially decrease the 
burden of anal and possibly HPV-related OP cancers, although further research is clearly 
needed. The increasing risk of liver cancer over time indicates a need to ensure universal 
hepatitis B virus (HBV) vaccination for HIV patients who are HBV seronegative, as already 
recommended (66), and to provide treatment of HBV infection using ART regimens with 
anti-HBV activity (66) and of hepatitis C virus (HCV) infection with recently approved 
interferon-free therapies (67, 68). Despite the calendar trend declines in ADC among HIV 
patients, KS and NHL remain major concerns such that efforts need to be intensified to 
promote early, sustained ART, the only known approach to prevention of these and possibly 
other cancers linked to immunosuppression (10) or inflammation (12). Finally, research is 
needed to follow-up on observational studies that suggest that statin use by HIV patients 
may reduce cancer risk (69–71), presumably due to their anti-inflammatory effects (72).
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There were limitations of our study. First, we did not include in our models secular trends in 
cancer screening, smoking, or viral co-infections since we did not comprehensively capture 
this information across cohorts, especially among uninfected subjects and non-cancer cases. 
However, among HIV-infected subjects with available data, we found the prevalence of 
HBV and HCV infection to be constant over calendar eras. We also chose not to adjust for 
CD4 and HIV RNA, since these factors are so intertwined with the survival improvements 
for HIV-infected subjects. Second, although our cancer validation ensured a standardized 
approach for cancer case ascertainment across cohorts, it is possible that differences in 
screening across cohorts resulted in variable ascertainment. However, variation in screening 
is not limited to our study population and would almost certainly be found in the general 
U.S. and Canadian HIV-infected population as well. Third, our measure of cumulative 
incidence relied on age-specific follow-up for only a small portion of each subject’s adult 
lifetime, under the assumption that the age-specific risk of cancer remained constant by birth 
cohort. We believe this assumption to be reasonable because our study sample included a 
relatively narrow birth cohort range, with substantial birth cohort overlap across calendar 
eras, similar variability within each calendar era, and similar birth cohort representation 
among HIV-infected and uninfected subjects. Nevertheless, it remains possible that some of 
our findings were driven in part by birth cohort effects, which would tend to manifest as 
artifactually steep cumulative incidence increases with age if earlier birth cohorts had a 
higher risk of cancer, such as has been shown for lung cancer (73). Fourth, there was limited 
follow-up in older ages, although comparison of cumulative cancer incidence estimates by 
age 65 and 75 years demonstrated that higher cancer risk at older ages noticeably influenced 
results for some cancer types. Fifth, nonsignificant trends associated with relatively wide 
95% CIs do not necessarily indicate the true absence of trends. Finally, although the HIV-
infected subjects in NA-ACCORD are highly generalizable to HIV-infected populations in 
the U.S. and Canada (33), the proportion of women and Hispanics was low, and the 
uninfected subjects may be less generalizable. However, with respect to the uninfected 
group, exchangeability with the HIV-infected group is more important for study inferences 
than is generalizability (74).
A major strength of our study was that we accounted for the competing risk of death, which 
allowed for a detailed assessment of whether trends in cumulative incidence resulted from 
actual changes in the cancer-type-specific hazard rate versus reductions in the all-cause 
mortality rate (31, 32). This approach also provided estimates of the cumulative incidence of 
cancer by age 75 years, a measure that has not been reported previously in this population 
and may have clinical and public health utility. This study was also one of few with a 
demographically comparable uninfected group (43, 75), which may reduce biases relating to 
access to care, surveillance for cancer, or prevalence of cancer risk factors, that can occur 
when general population comparison groups are used.
In summary, the effectiveness of ART has enabled HIV patients to live long enough to 
experience cancer. Thus, the increasing cumulative incidence trends for anal, colorectal, and 
liver cancers and the lack of evidence for trends for lung cancer, HL, and melanoma were 
driven by the steeply declining mortality rate, without which these trends would have been 
absent or declining, according to the cancer-specific hazard rate trends. The high cumulative 
incidences by age 75 years for KS, NHL, and lung cancer indicate that public health efforts 
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need to be intensified to promote early, sustained ART, smoking cessation, and lung cancer 
screening. As the HIV-infected population ages, future estimates could be stratified by 
levels of cancer risk factors such as CD4 count, smoking, alcohol consumption, and HBV or 
HCV infection, to more accurately inform patients and providers about risk and to help 
further target prevention efforts.
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Figure 1. Cumulative cancer incidence by calendar era and cancer type for HIV-infected 
subjects with age as the time scale, NA-ACCORD, 1996–2009
KS, Kaposi sarcoma; NHL, Non-Hodgkin’s lymphoma; HL, Hodgkin lymphoma. 
Cumulative incidence (i.e., cancer risk) curves for calendar eras 1996–1999 (light gray dash-
dot line), 2000–2004 (dark gray dash line), and 2005–2009 (black solid line), were obtained 
using non-parametric estimators for competing risk events. Numbers associated with curves 
represent cumulative incidence (%) by age 75 years; *P<0.05 compared with reference 
(1995–1999 era); ** P<0.01 compared with reference (1995–1999 era).
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Figure 2. Cumulative cancer incidence by calendar era and cancer type for uninfected subjects 
with age as the time scale, NA-ACCORD, 1996–2009
KS, Kaposi sarcoma; NHL, Non-Hodgkin’s lymphoma; HL, Hodgkin lymphoma. 
Cumulative incidence (i.e., cancer risk) curves for calendar eras 1996–1999 (light gray dash-
dot line), 2000–2004 (dark gray dash line), and 2005–2009 (black solid line), were obtained 
using non-parametric estimators for competing risk events. Numbers associated with curves 
represent cumulative incidence (%) by age 75 years; *P<0.05 compared with reference 
(1995–1999 era); ** P<0.01 compared with reference (1995–1999 era).
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Table 1
Calendar trends in selected characteristics by HIV infection status, NA-ACCORD, 1996–2009
1996–1999 2000–2004 2005–2009
HIV-infected (n=86,620)
Person-years 79,351 204,240 192,069
Median age, years (IQR)1 42 (36, 49) 44 (37, 51) 47 (40, 54)
Median year of birth (IQR)1 1955 (1949, 1961) 1957 (1950, 1964) 1959 (1952, 1966)
% men1 87 85 86
On antiretroviral therapy, % 39 67 74
Median CD4, cells/ul (IQR)1 309 (152, 490) 350 (187, 545) 382 (222, 570)
Median HIV RNA, copies/ml (IQR)1 2,729 (400, 27744) 748 (100, 21321) 244 (100, 11018)
Race, %1
 White 45 44 43
 Black 43 40 39
 Hispanic 3 7 7
 Other 2 3 3
 Unknown 6 7 8
HIV risk group, %1,2
 MSM 39 42 43
 IDU 24 19 17
 Other 22 25 25
 Unknown 15 14 15
Hepatitis B virus infected, %1,3 3 4 4
Hepatitis C virus infected, %1,3 22 21 20
Crude mortality rate (95% CI)4 5,140 (4985, 5301) 3,913 (3828, 3999) 2,844 (2770, 2921)
Uninfected (n=196,987)
Person-years 306,569 669,647 871,716
Median age, years (IQR)1 42 (36, 49) 45 (38, 52) 48 (41, 55)
Median year of birth (IQR)1 1955 (1948, 1961) 1956 (1949, 1963) 1957 (1950, 1964)
% men1 93 93 93
Race, %1
 White 40 38 38
 Black 24 23 24
 Hispanic 5 5 5
 Other 7 7 7
 Unknown 23 26 25
Crude mortality rate (95% CI)4 669 (641, 699) 870 (848, 892) 863 (844, 883)
CI, confidence interval; MSM, men who have sex with men; IDU, injection drug users; IQR, interquartile range
1
Age, year of birth, sex, antiretroviral therapy use, CD4, HIV RNA, race, HIV risk group, and hepatitis B and C infection at entry into calendar era
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2
One large cohort that did not have information on HIV risk group was omitted from these frequencies
3
Three cohorts that did not provide information on hepatitis B virus infection and two cohorts that did not provide information on hepatitis C virus 
infection were omitted from these frequencies. Also, these are minimum values because in the cohorts that did provide information, the majority of 
subjects were not tested.
4
Per 100,000 person-years
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Table 2




n rate1 n rate1
Kaposi sarcoma 612 130.4 3 0.2
Non-Hodgkin’s lymphoma 725 153.5 233 12.6
Lung 614 129.3 839 45.4
Anal 285 60.1 22 1.2
Colorectal 173 36.4 510 27.7
Liver 220 46.3 201 10.9
Hodgkin lymphoma 159 33.5 36 1.9
Melanoma 78 16.4 268 14.5
Oral cavity/pharyngeal 163 34.3 340 18.4
Death 17,534 3,686 15,400 833
1
Incidence rate per 100,000 person-years
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Table 3




65 years 75 years 65 years 75 years
% (95% CI) % (95% CI) % (95% CI) % (95% CI)
Kaposi sarcoma 4.3 (3.8, 5.0) 4.4 (3.8, 5.2) 0.00 (0.00, 0.01) 0.01 (0.00, 0.03)
Non-Hodgkin’s lymphoma 4.1 (3.6, 4.6) 4.5 (4.0, 5.1) 0.4 (0.3, 0.4) 0.7 (0.6, 0.8)
Lung 2.2 (2.0, 2.4) 3.4 (3.1, 3.7) 1.3 (1.1, 1.4) 2.8 (2.5, 3.0)
Anal 1.3 (1.1, 1.5) 1.5 (1.3, 1.7) 0.03 (0.02, 0.04) 0.05 (0.03, 0.08)
Colorectal 0.6 (0.5, 0.7) 1.0 (0.8, 1.2) 0.8 (0.7, 0.9) 1.5 (1.3, 1.6)
Liver 0.8 (0.7, 0.9) 1.1 (1.0, 1.3) 0.3 (0.3, 0.4) 0.4 (0.3, 0.5)
Hodgkin lymphoma 0.9 (0.7, 1.0) 0.9 (0.7, 1.1) 0.06 (0.04, 0.08) 0.09 (0.05, 0.12)
Melanoma 0.4 (0.3, 0.5) 0.5 (0.4, 0.6) 0.5 (0.4, 0.6) 0.6 (0.5, 0.7)
Oral cavity/pharyngeal 0.6 (0.5, 0.7) 0.8 (0.7, 1.0) 0.6 (0.5, 0.6) 0.8 (0.7, 1.0)
CI, confidence interval
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